EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSAPEG00000009322
Gene Symbol: SCN4A
2 Cross references
187 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSAPEG00000018655
Gene Symbol: SCN8A
2 Cross references
218 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSAPEG00000023254
Gene Symbol: SLC10A2
1 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSAPEG00000003925
Gene Symbol: SLC18A2
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSAPEG00000018854
Gene Symbol: SLC29A1
2 Cross references
207 Possible Orthologues:

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSAPEG00000003912
Gene Symbol: SLC29A1A
1 Cross references
204 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSAPEG00000008526
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSAPEG00000024478
Gene Symbol: SLC5A2
1 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSAPEG00000014269
Gene Symbol: SLC6A1A
1 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSAPEG00000005275
Gene Symbol: SLC6A1B
1 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSAPEG00000009442
Gene Symbol: SLC6A2
1 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSAPEG00000015126
Gene Symbol: SLC6A3
1 Cross references
167 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).